

In the Claims

1. (canceled)
2. (canceled)
3. A method of treating or preventing the onset of diabetic retinopathy in a patient comprising administering somatostatin to said patient and co-administering a thyroid-related substance.
4. The method of claim 3, wherein said somatostatin is octreotide, lanreotide, vapreotide, MK 678, L-363-377, L-797,591, L-779,976, L-796-778, L-803,087, L-817,818, or combinations thereof.
5. (previously amended) The method of claim 3, wherein said thyroid related substance is thyroid hormone, thyroxine, thyrotropin, thyroid stimulating hormone, or analogues or pharmaceutically acceptable salts or derivatives thereof that have similar biological functionality or effect in the body
6. A composition useful for treating or preventing the onset of DR comprising a mixture of somatostatin and a thyroid-related substance.
7. A kit comprising at least one container having somatostatin and a thyroid-related substance disposed therein.
8. The kit of claim 7 further comprising a syringe for administration of the somatostatin and thyroid-related substance.
9. The kit of claim 8 wherein at least one container is one or more syringes having somatostatin and thyroid-related substance disposed in either one syringe as a mixture or in separate syringes.
10. (previously amended) The kit of claim 7 wherein the somatostatin and thyroid-related substance are in a form suitable for oral administration.

Do not
inter.
JRL
10-9-2003